178 related articles for article (PubMed ID: 31107896)
21. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
[TBL] [Abstract][Full Text] [Related]
22. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
[TBL] [Abstract][Full Text] [Related]
23. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
[TBL] [Abstract][Full Text] [Related]
24. Associations between serum mineral metabolism parameters and mortality in patients on peritoneal dialysis.
Wu M; Wu H; Huang X; Ye H; Huang F; Yu X; Yang X
Nephrology (Carlton); 2019 Nov; 24(11):1148-1156. PubMed ID: 30565789
[TBL] [Abstract][Full Text] [Related]
25. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
Isakova T; Cai X; Lee J; Katz R; Cauley JA; Fried LF; Hoofnagle AN; Satterfield S; Harris TB; Shlipak MG; Sarnak MJ; Ix JH;
J Bone Miner Res; 2016 Apr; 31(4):742-8. PubMed ID: 26590361
[TBL] [Abstract][Full Text] [Related]
26. Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis.
Zhong Z; Feng S; Fu D; Li B; Li Z; Mao H
Perit Dial Int; 2024 May; 44(3):194-202. PubMed ID: 38449341
[TBL] [Abstract][Full Text] [Related]
27. Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults.
Panwar B; Judd SE; Wadley VG; Jenny NS; Howard VJ; Safford MM; Gutiérrez OM
JAMA Cardiol; 2018 Apr; 3(4):318-325. PubMed ID: 29516098
[TBL] [Abstract][Full Text] [Related]
28. Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial.
Mercadal L; Tezenas du Montcel S; Chonchol MB; Debure A; Depreneuf H; Servais A; Bassilios N; Assogba U; Allouache M; Prié D
Am J Nephrol; 2018; 48(5):349-356. PubMed ID: 30408788
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis.
Humalda JK; Riphagen IJ; Assa S; Hummel YM; Westerhuis R; Vervloet MG; Voors AA; Navis G; Franssen CF; de Borst MH;
Nephrol Dial Transplant; 2016 Sep; 31(9):1494-501. PubMed ID: 26602863
[TBL] [Abstract][Full Text] [Related]
30. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.
Floege J; Kim J; Ireland E; Chazot C; Drueke T; de Francisco A; Kronenberg F; Marcelli D; Passlick-Deetjen J; Schernthaner G; Fouqueray B; Wheeler DC;
Nephrol Dial Transplant; 2011 Jun; 26(6):1948-55. PubMed ID: 20466670
[TBL] [Abstract][Full Text] [Related]
31. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?
Nowak A; Artunc F; Serra AL; Pollock E; Krayenbühl PA; Müller C; Friedrich B
Kidney Blood Press Res; 2015; 40(3):266-76. PubMed ID: 25997652
[TBL] [Abstract][Full Text] [Related]
32. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
[TBL] [Abstract][Full Text] [Related]
33. Optimal targets of chronic kidney disease-mineral and bone disorder markers for Chinese patients with maintenance peritoneal dialysis: a single-center retrospective cohort study.
Chen L; Tang X; Zheng H; Wang H; Xia P; Wang Y; Zhao X; Zhou Z; Qiu L; Li X
Ren Fail; 2022 Dec; 44(1):336-345. PubMed ID: 35380083
[TBL] [Abstract][Full Text] [Related]
34. Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.
Montford JR; Chonchol M; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Kendrick J;
Am J Nephrol; 2013; 37(3):183-90. PubMed ID: 23428834
[TBL] [Abstract][Full Text] [Related]
35. Association of CKD-MBD Markers with All-Cause Mortality in Prevalent Hemodialysis Patients: A Cohort Study in Beijing.
Li D; Zhang L; Zuo L; Jin CG; Li WG; Chen JB
PLoS One; 2017; 12(1):e0168537. PubMed ID: 28045985
[TBL] [Abstract][Full Text] [Related]
36. Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The São Paulo Ageing & Health (SPAH) Study.
Domiciano DS; Machado LG; Lopes JB; Figueiredo CP; Caparbo VF; Oliveira RM; Scazufca M; McClung MR; Pereira RM
J Bone Miner Res; 2016 Jun; 31(6):1146-57. PubMed ID: 26814375
[TBL] [Abstract][Full Text] [Related]
37. Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.
Liu Y; Lee WC; Cheng BC; Li LC; Lee CH; Chang WX; Chen JB
Biomed Res Int; 2016; 2016():1523124. PubMed ID: 28003998
[No Abstract] [Full Text] [Related]
38. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
[TBL] [Abstract][Full Text] [Related]
39. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
[TBL] [Abstract][Full Text] [Related]
40. Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: A prospective multicenter cohort study.
Lee JE; Lim JH; Jang HM; Kim YS; Kang SW; Yang CW; Kim NH; Kwon E; Kim HJ; Park JM; Jung HY; Choi JY; Park SH; Kim CD; Cho JH; Kim YL;
PLoS One; 2017; 12(10):e0185853. PubMed ID: 28973026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
